P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
Myrthe van Dijk(University Medical Center Utrecht), Eduard J. van Beers(Utrecht University), Brigitte van Oirschot(Utrecht University), Marjon H. Cnossen(Erasmus MC), Erfan Nur(Sanquin), Minke A.E. Rab(Utrecht University), Wouter W. van Solinge(Utrecht University), Roger E. G. Schutgens(University Medical Center Utrecht), Cleo Derichs(Utrecht University), Anita W. Rijneveld(Erasmus MC Cancer Institute), Bart J. Biemond(Amsterdam University Medical Centers), Richard van Wijk(Utrecht University), Judith Jans(University Medical Center Utrecht), Jennifer Bos(Utrecht University), Marije Bartels(University Medical Center Utrecht)
Cited by 0
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
|Blood|2017|300
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
|Haemophilia|2011|244
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|The Lancet Haematology|2021|237